Clinical Trial Update: A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating TGFβ-imprinted, ex vivo expanded universal donor NK cell infusions in combination with gemcitabine and docetaxel for relapse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Sarcoma
• Sarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)
• TGFβ-imprinted universal donor NK cell infusion (universal donor NK cell infusion)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed | Phase 1, Phase 2 | Status: RECRUITING